Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
400 participants
OBSERVATIONAL
2009-01-01
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In the present study, we investigated the incidence and risk factors of influenza infection on in myasthenia gravis patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Profiles in Myasthenia Gravis
NCT05095103
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
NCT05408702
Interleukin and Autoantibodies in Myasthenia Gravis.
NCT05301153
Digital Phenotyping and Lifestyle Intervention in Patients with Myasthenia Gravis
NCT05992025
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
NCT05214612
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients who meet the inclusion and non inclusion criteria and do not object to participate in the study will be collected in a database for analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Myasthenic patients hospitalized in intensive care.
* Patients with confirmed influenza infection
Exclusion Criteria
* Other neuromuscular diseases,
* Patient opposing the use of his data
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre d'Investigation Clinique et Technologique 805
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rania BOUNAB, Dr
Role: STUDY_DIRECTOR
Raymond Poincaré Hospital
References
Explore related publications, articles, or registry entries linked to this study.
Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol. 2018 Jan;16(1):60. doi: 10.1038/nrmicro.2017.146. Epub 2017 Nov 7.
Tackenberg B, Schneider M, Blaes F, Eienbroker C, Schade-Brittinger C, Wellek A, Deschauer M, Eickmann M, Klenk HD, Muller HH, Sommer N. Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial). EBioMedicine. 2018 Feb;28:143-150. doi: 10.1016/j.ebiom.2018.01.007. Epub 2018 Jan 10.
Friman G, Schiller HH, Schwartz M. Distubed neuromuscular transmission in viral infections. Scand J Infect Dis. 1977;9(2):99-103. doi: 10.3109/inf.1977.9.issue-2.08.
Rosciszewska D, Bluszcz M, Kurek H. [Antibodies for DNA and RNA viruses in the serum of myasthenia patients. Preliminary report]. Neurol Neurochir Pol. 1981 Sep-Dec;15(5-6):541-4. Polish.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIC1429
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.